Table 3.
Univariate and multivariate analyses of prognostic factors for cervical cancer patients
| Variable | Overall survival | Disease free survival | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 3-Year Rate | 5-Year Rate | P e | Adjusted HR | P b | 3-Year Rate | 5-Year Rate | P e | Adjusted HR | P f | ||
| (95% CI) | (95% CI) | (95% CI) f | (95% CI) | (95% CI) | (95% CI)f | ||||||
| Age, years | |||||||||||
| < 40 | 93.18 (80.33, 97.75) | 93.18 (80.33, 97.75) | 0.634 | 1.00 | 86.43 (72.24, 93.67) | 78.58 (62.60, 88.34) | 0.956 | 1.00 | |||
| 40–50 | 91.20 (84.67, 95.03) | 85.39 (76.26, 91.21) | 1.74 (0.49, 6.20) | 0.390 | 83.84 (76.07, 89.26) | 78.48 (68.81, 85.46) | 0.72 (0.32, 1.60) | 0.417 | |||
| > 50 | 91.75 (85.20, 95.47) | 86.99 (79.22, 92.00) | 1.09 (0.30, 4.04) | 0.893 | 87.78 (80.55, 92.45) | 78.01 (68.46, 84.99) | 0.56 (0.25, 1.30) | 0.177 | |||
| Histologic typea | |||||||||||
| SCC | 91.77 (87.87, 94.46) | 87.07 (81.97, 90.81) | 0.943 | 85.79 (81.13, 89.37) | 77.96 (71.96, 82.82) | 0.478 | |||||
| AC/ASC | 87.50 (38.70, 98.14) | 87.50 (38.70, 98.14) | 87.50 (38.70, 98.14) | 87.50 (38.70, 98.14) | |||||||
| FIGO stageb | |||||||||||
| I | 95.82 (89.23, 98.41) | 94.73 (87.79, 97.77) | <0.001 | 1.00 | 93.83 (86.78, 97.18) | 86.60 (75.90, 92.76) | <0.001 | 1.00 | |||
| II | 95.68 (90.63, 98.04) | 88.83 (79.72, 94.00) | 0.98 (0.27, 3.50) | 0.970 | 89.86 (83.48, 93.87) | 84.14 (76.10, 89.65) | 1.20 (0.43, 3.36) | 0.735 | |||
| III | 74.66 (59.67, 84.76) | 70.20 (54.87, 81.17) | 3.40 (0.92, 12.52) | 0.066 | 66.66 (51.44, 78.08) | 53.52 (37.74, 66.96) | 4.54 (1.53, 13.42) | 0.006 | |||
| IV | 60.00 (12.57, 88.18) | 40.00 (5.20, 75.28) | 9.91 (1.87, 52.39) | 0.007 | 16.67 (0.77, 51.68) | 16.67 (0.77, 51.68) | 13.21 (3.24, 53.82) | <0.001 | |||
| Differentiation | |||||||||||
| Poor | 90.36 (81.64, 95.07) | 86.83 (76.49,92.82) | 0.383 | 83.23 (73.31, 89.71) | 68.83 (55.26, 79.03) | 0.068 | |||||
| Moderate | 90.68 (83.80, 94.73) | 88.08 (80.70,92.77) | 88.27 (80.98, 92.88) | 82.83 (73.70, 89.02) | |||||||
| Well | 90.91 (50.81, 98.67) | 72.73 (37.08,90.28) | 63.64 (29.69, 84.52) | 63.64 (29.69, 84.52) | |||||||
| Unclassified | |||||||||||
| Treatment§ | |||||||||||
| Surgery | 100 | 98.53 (90.02, 99.79) | 0.004 | 1.00 | 96.05 (88.24, 98.71) | 84.25 (66.36, 93.09) | 0.019 | 1.00 | |||
| Surgery plus CT/RT/CRT | 100 | 93.75 (63.23, 99.10) | 3.98 (0.25, 64.19) | 0.331 | 95.00 (69.47, 99.28) | 95.00 (69.47, 99.28) | 0.43 (0.52, 3.56) | 0.433 | |||
| CCRT | 90.02 (83.99, 93.87) | 82.55 (74.02, 88.49) | 8.26 (0.87, 78.75 | 0.066 | 83.34 (76.34, 88.43) | 73.83 (65.27, 80.60) | 1.44 (0.44, 4.74) | 0.545 | |||
| CR or RT | 79.55 (64.38, 88.79) | 79.55 (64.38, 88.79) | 13.91 (1.59, 121.54) | 0.017 | 73.37 (57.89, 83.91) | 73.37 (57.89, 83.91) | 1.92 (0.63, 5.88) | 0.253 | |||
| HPV16 | |||||||||||
| Negative | 83.09 (73.10, 89.63) | 81.77 (71.57, 88.60) | 0.037 | 1.00 | 82.89 (72.81, 89.50) | 75.71 (64.69, 83.71) | 0.342 | ||||
| Positive | 95.17 (91.21, 97.37) | 88.93 (82.31, 93.17) | 0.36 (0.18, 0.74) | 0.005 | 87.07 (81.70, 90.95) | 79.03 (71.40, 84.84) | |||||
| HPV18 | |||||||||||
| Negative | 91.87 (87.80, 94.62) | 87.58 (82.23, 91.40) | 0.404 | 86.49 (81.69, 90.11) | 78.76 (72.58, 83.71) | 0.69 | |||||
| Positive | 90.04 (72.14, 96.69) | 83.12 (64.02, 92.62) | 80.85 (62.18, 90.93) | 74.63 (52.38, 87.60) | |||||||
| HR-HPV speciesd | |||||||||||
| Alpha-7 | 74.38 (58.47, 84.93) | 71.81 (55.65, 82.94) | <0.001 | 1.00 | 76.32 (60.41, 86.51) | 62.96 (45.04, 76.47) | 0.005 | 1.00 | |||
| Alpha-9 | 94.34 (90.44, 96.67) | 90.42 (84.82, 94.02) | 0.17 (0.08, 0.37) | <0.001 | 87.89 (82.93, 91.47) | 80.88 (74.33, 85.92) | 0.32 (0.17, 0.59) | <0.001 | |||
| HR-HPV pattern | |||||||||||
| Single | 90.90 (86.61, 93.86) | 87.04 (81.66, 90.94) | 0.939 | 85.47 (80.51, 89.25) | 77.41 (71.06, 82.53) | 0.389 | |||||
| Multiple | 97.30 (82.32, 99.61) | 87.77 (70.52, 95.24) | 88.83 (72.85, 95.67) | 85.54 (68.53, 93.75) | |||||||
aSCC, squamous cell carcinoma; AC, adenocarcinoma; ASC, adeno-squamous carcinoma
bFIGO, International Federation of Gynecology and Obstetrics
cCT, chemotherapy; RT, radiotherapy; CRT, chemoradiotherapy; CCRT, concurrent chemoradiotherapy
dHR-HPV, high risk human papillomavirus
eCalculated by using the log-rank test. Bold values indicate P < 0.05
fAdjusted for age, FIGO stage, and treatment in the Cox regression models